Synchron Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
125
- Latest Deal Type
-
2ndary - Private
- Investors
-
52
Synchron General Information
Description
Developer of an implantable stent-rode designed to create a brain-computer interface. The company offers a minimally invasive implantable device embedded with electrode arrays that interpret signals from the brain to modulate neural activity in specific regions, enabling patients with motor impairments to regain some level of control over digital devices, prosthetics, or other assistive technologies using their thoughts.
Contact Information
Website
www.synchron.comCorporate Office
- Navy Yard
- Brooklyn
- New York, NY 11205
- United States
Corporate Office
- Navy Yard
- Brooklyn
- New York, NY 11205
- United States
Synchron Timeline
Synchron Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Secondary Transaction - Private | 01-Nov-2026 | Completed | Clinical Trials - General | |||
| 8. Later Stage VC (Series D) | 01-Aug-2025 | Completed | Clinical Trials - General | |||
| 7. Later Stage VC (Series C) | 02-Dec-2022 | Completed | Clinical Trials - General | |||
| 6. Angel (individual) | 07-Feb-2022 | Completed | Clinical Trials - General | |||
| 5. Grant | 26-Aug-2021 | Completed | Clinical Trials - General | |||
| 4. Later Stage VC (Series B) | 03-Jun-2021 | Completed | Clinical Trials - General | |||
| 3. Grant | 24-Jul-2020 | Completed | Clinical Trials - General | |||
| 2. Early Stage VC (Series A) | 01-Mar-2018 | $10M | $25M | Completed | Product Development | |
| 1. Seed Round | $15M | $15M | Completed | Product Development |
Synchron Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series D | ||||||||
| Series C-1 | ||||||||
| Series C | ||||||||
| Series B-1 | ||||||||
| Series B | 2,849,155 | $0.000100 | 8% | $12.64 | $12.64 | 1x | $12.64 | 12.75% |
| Series A | 1,770,224 | $0.000100 | 8% | $2 | $2 | 1x | $2 | 7.92% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Synchron Comparisons
Industry
Financing
Details
Synchron Competitors (9)
One of Synchron’s 9 competitors is Precision Neuroscience, a Venture Capital-Backed company based in New York, NY.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Precision Neuroscience | Venture Capital-Backed | New York, NY | ||||
| Neuralink | Venture Capital-Backed | Fremont, CA | ||||
| Blackrock Neurotech | Venture Capital-Backed | Salt Lake City, UT | ||||
| Neurable | Venture Capital-Backed | Boston, MA | ||||
| Paradromics | Venture Capital-Backed | Austin, TX |
Synchron Patents
Synchron Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260339437-A1 | Use of secondary data during neural decoding in brain computer interface systems | Pending | 25-Apr-2025 | ||
| WO-2026224673-A1 | Use of secondary data during neural decoding in brain computer interface systems | Pending | 25-Apr-2025 | ||
| WO-2026207178-A1 | Adaptive user interfaces for brain computer interface systems | Pending | 26-Mar-2025 | ||
| US-20260277327-A1 | Context-aware neural signal decoding | Pending | 16-Mar-2025 | ||
| WO-2026198344-A1 | Context-aware neural signal decoding | Pending | 16-Mar-2025 | G06F3/015 |
Synchron Signals
Synchron Investors (52)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| 3cap | Venture Capital | Minority | ||
| Armyn Capital | Venture Capital | Minority | ||
| Axial Partners (United States) | Venture Capital | Minority | ||
| Destiny | Venture Capital | Minority | ||
| Double Point Ventures | Venture Capital | Minority |
Synchron Investments & Acquisitions (3)
Synchron’s most recent deal was a Corporate with Acquandas. The deal was made on 01-Feb-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Acquandas | 01-Feb-2024 | Corporate | Other Commercial Products | ||
| Rare Element Resources | 02-Oct-2017 | PIPE | Gold Mining | ||
| SmartStent | 04-May-2016 | Merger/Acquisition | Diagnostic Equipment |
Synchron FAQs
-
When was Synchron founded?
Synchron was founded in 2016.
-
Where is Synchron headquartered?
Synchron is headquartered in New York, NY.
-
What is the size of Synchron?
Synchron has 125 total employees.
-
What industry is Synchron in?
Synchron’s primary industry is Therapeutic Devices.
-
Is Synchron a private or public company?
Synchron is a Private company.
-
What is Synchron’s current revenue?
The current revenue for Synchron is .
-
How much funding has Synchron raised over time?
Synchron has raised $340M.
-
Who are Synchron’s investors?
3cap, Armyn Capital, Axial Partners (United States), Destiny, and Double Point Ventures are 5 of 52 investors who have invested in Synchron.
-
Who are Synchron’s competitors?
Precision Neuroscience, Neuralink, Blackrock Neurotech, Neurable, and Paradromics are some of the 9 competitors of Synchron.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process